Multimodal neuroimaging study of regulating menstruation and promoting pregnancy acupuncture therapy in patients with polycystic ovary syndrome

acupuncture and tuina

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006569

Enrollment

Unknown

Registered

2022-09-06

Start date

2022-08-24

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovarian syndrome

Interventions

Healthy people group:nonintervention

PCOS group :acupuncture

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: PCOS: ? Sparse ovulation or anovulation (clinical manifestations are sparse menstruation and amenorrhea); ? Clinical and/or biochemical features of hyperandrogenemia; ? Polycystic changes in ovary. Two of the above three are true. Healthy women: Good physical condition, regular menstrual cycle, normal ovarian function, normal gynecological color doppler ultrasound, right-handedness, no organic or serious functional diseases, no history of mental illness, no MRI contraindications, etc. ? Women aged 18-40; ? Right hand; ? No acupuncture treatment in the past 1 month; ? Those who voluntarily participated in the experiment and insisted on treatment and signed informed consent.

Exclusion criteria

Exclusion criteria: ? Complicated with other endocrine system diseases, including congenital adrenal hyperplasia, adrenal tumor, Cushing's syndrome, ovarian or adrenal tumor secreting androgen, pituitary prolactinoma, diabetes mellitus, thyroid disease, etc. ? Complicated with serious primary diseases, such as serious diseases of cardiovascular and cerebrovascular system, respiratory system, liver, kidney, digestive system, blood system, immune system and neuropsychiatric system; (3) history of thrombosis or thromboembolism; (4) Substance abuse in the past 3 months, including serious alcohol abuse, smoking (1 pack or more per day), drug abuse; ? Taking dingkundan or Dayin-35 or other oral contraceptives and sex hormone drugs within the last 3 months; ? Pregnant and lactating women, and women within 1 year after delivery; There are metal in the body, claustrophobia and other mri contraindications.

Design outcomes

Primary

Measure	Time frame
Neuroimaging index;LH/FSH;	—

Secondary

Measure	Time frame
Ferriman-gallway Hair Rating Scale;Menstruation situation;Self-rating Depression Scale;GAGS table;self-rating anxiety scale;	—

Countries

China

Contacts

Public Contactxu chengchao

Shandong Provinicial Third Hospital,Shandong University

18253129068@163.com18253129068

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026